By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Supernus Pharmaceuticals 

1550 East Gude Drive

Rockville  Maryland  20850  U.S.A.
Phone: 301-838-2501 Fax: n/a


SEARCH JOBS



Key Statistics


Email:
Ownership: Public

Web Site: Supernus Pharmaceuticals
Employees:
Symbol: SUPN
 



Industry
Pharmaceutical






Company News
Supernus Pharmaceuticals (SUPN) Selects DSG, Inc. For EDC And IWRS In Phase III Clinical Studies On Impulsive Aggression In Pediatric Patients Treated For Attention Deficit/Hyperactivity Disorder (ADHD) 4/1/2016 10:32:01 AM
Supernus Pharmaceuticals (SUPN) Announces Record Fourth Quarter And Full Year 2015 Financial Results 3/3/2016 7:47:28 AM
Supernus Pharmaceuticals (SUPN) Announces Distribution Of Common Stock By NEA 12/4/2015 7:58:39 AM
Supernus Pharmaceuticals (SUPN) To Attend Guggenheim Securities Boston Healthcare Conference 12/3/2015 8:44:47 AM
Supernus Pharmaceuticals (SUPN) Announces Distribution Of Common Stock By NEA 11/13/2015 7:48:29 AM
Supernus Pharmaceuticals (SUPN) To Present At Two Investor Conferences 11/10/2015 8:29:08 AM
Supernus Pharmaceuticals (SUPN) Announces Third Quarter 2015 Financial Results And Raises 2015 Guidance 11/4/2015 7:33:21 AM
Supernus Pharmaceuticals (SUPN) Announces FDA Acceptance Of Snda To Add Migraine To Trokendi XR Label 10/23/2015 8:03:22 AM
Supernus Pharmaceuticals (SUPN) To Host Third Quarter 2015 Earnings Conference Call 10/21/2015 7:42:46 AM
Supernus Pharmaceuticals (SUPN) Announces Settlement With Par On Trokendi XR Patent Litigation 10/15/2015 7:44:36 AM
12345678910...
//-->